The effects of platelet-activating factor (PAF) were studied on isolated feline basilar arteries (BAs) and human pial arteries (PAs). PAF contracted the BAs by 67% of the contraction induced by 124 mM K + and the PAs by 80%. The contraction in BAs was unaffected by both indomethacin and the thromboxane receptor antag onist AH23848. PAF relaxed prostaglandin F2a-con tracted arteries. In BAs 10-6 M PAF reduced the con-Platelet-activating factor (PAF) is an active lipid released in response to different stimuli, for in stance, inflammation (Goldstein et aI., 1986). It is produced by a variety of cells such as platelets, leukocytes, and endothelial cells (Braquet et aI.,
. PAF may contribute to the development of postischemic brain damage (Spinnewyn et aI., 1987) , and PAF antagonists seem to increase CBF during the reperfusion period (Panetta et al., 1987) . Armstead et al. (1988) have recently found PAF to be a potent constrictor of pial arterioles in vivo in newborn pigs. These observations suggest that PAF is mainly a cerebral vasoconstrictor, but the direct effects of PAF have not been studied in cerebral arteries.
The present study was performed to examine the effects of PAF on isolated feline and human cere bral arteries. Since it has been suggested that the effects of PAF may be mediated by prostaglandins (PGs) and/or thromboxane (Tx) A2 (Braquet et aI., traction by 17% and in PAs by 47%. The relaxant effects in both arteries were unaffected by indomethacin. In con clusion, P AF can act both as a constrictor and as a dilator of isolated feline and human cerebral arteries. The effects are seemingly unrelated to vascular prostanoid produc tion. Key Words: Feline basilar arteries-Human pial ar teries-Platelet-activating factor. 1987), these possibilities were also addressed. For this purpose the cyclooxygenase inhibitor indo methacin and the Tx receptor antagonist AH23848 (Brittain et aI., 1985) were used.
MATERIAL AND METHODS
Cats (2.2-2.8 kg) were exsanguinated during sodium pentobarbital (30 mg/kg i.p.) anesthesia. The brains were removed and the basilar artery (BA) was dissected free from the brainstem. Human pial arteries (PAs) were re moved together with adjacent parts of normal cortex in patients (16--69 years of age) undergoing frontal or tem poral lobectomies due to underlying gliomas. The speci mens were immersed in cold (-4°C) Krebs solution and the arteries were freed from brain tissues. All vessels were stored in cold Krebs solution for "",6 h.
Ring segments, 1-1.5 (BA) or 2-3 (PA) mm in length, of the arteries were suspended between metal prongs in or gan baths containing 2.5 ml of a Krebs solution (for com position, see below). The contents of the baths were maintained at 37°C and gassed with a mixture of 5% CO2 and 95% O2, One of the prongs was connected to a Grass FT03C transducer and the other prong was attached to a displacement device (for details, see Hogestatt et aI., 1983) . The vessels were subjected to a tension of -2 mN for BA and 4 mN for PA.
The following solutions were used: (a) a normal Krebs solution containing (in mM) NaCI 119, NaHC03 15, KCl 4.6, CaCl2 1.5, NaH2P04 1.2, MgCl2 1.2, and glucose 11; (b) a depolarizing solution containing 124 mM K +, ob tained by equimolar substitution of NaCI with KCI.
The drugs used were PAF (acetyl glycerol ether phos phoryl choline, semisynthetic; Sigma, st. Louis, MO, U.S.A.) supplied dissolved in chloroform and diluted with phosphate buffer; PGF2o< (Amoglandin; Astra, S6dertiilje, Sweden); indomethacin (Dumex, Copen hagen, Denmark); and AH23848 (Glaxo, Ware, England). All concentrations are given as the final concentrations in the organ baths in moles per liter (molar).
Two reproducible (± 10%) contractions were first ob tained on each vessel segment with the depolarizing so lution containing K + and all subsequent contractions were expressed as a percentage of the mean of these two contractions. The contraction induced by K + amounted to 8.1 ± 0.3 mN (n = 59) in BA and 6.3 ± 0.7 mN (n = 18) in PA. Since the response of PAF shows marked tachyphylaxis presently confirmed in pilot experiments on the contractile effect of PAF), only one concentration of P AF was tested on each vessel segment. To study relaxant effects, the arteries were con tracted by 2 x 10-5 M PGF2o<' The responses to PAF were expressed as the percentage reduction of the preex isting contraction. Results are presented as mean values ± SEM, n denoting the number of experiments. Signifi cance between groups of data was evaluated with Stu dent's t test if not more than two groups were compared; otherwise the Bonferroni correction was applied and the test was preceded by the analysis of variance (ANOV A). Probability values (p) of <5 x 10-2 were accepted as significant.
RESULTS P AF at 10 -5 M induced a nonsustained contrac tion amounting to 67 ± 6% of the K + (124 mM) induced response (n = 6) in BAs and 80 ± 7% (n = 5) in PAs. The lowest concentration at which con tractions were consistently induced in both vessels was 10-7 M (Fig. 1) . PAF concentrations above 10-5 M could not be tested owing to the low water solubility of the substance. Pretreatment of BAs with indomethacin (10 -6 M for 15 min) or AH23848 (10-6 Mfor 30 min) had no effect on the contractile response to 10-6 M PAF (Fig. 1) . PGF2Ct (2 X 10-5 M) elicited stable contractions in both arteries amounting to 90 ± 3% (n = 6) in BAs and 91 ± 5% (n = 5) in PAs. PAF relaxed these PGF2Ct-contracted arteries (Fig. 2) , the re sponse at 10-6 M amounting to 17 ± 3% (n = 6) in BAs and 47 ± 9% (n = 5) in PAs. The relaxant effect was significantly (p = 1.37 X 10-2, t test with Bonferroni correction; p = 5.2 X 10-3, ANOVA) more marked in the latter. P AF could not be tested at higher concentrations since adding the amount of solvent (250 fl.l) needed to attain a PAF concentra tion of 10 -5 M in the organ bath induced a marked relaxation (50-90%) in PGF2Ct-contracted arteries. The solvent was inactive when only 25 fl.l was added. Indomethacin (10-6 M) pretreatment of the BAs did not significantly (t test and ANOV A) affect the PAF-induced relaxation (Fig. 2) . In separate ex periments on PAs, the relaxation induced by 10-6 M PAF increased insignificantly (t test) from 53 ± 12 to 59 ± 22% (n = 5) after pretreatment with 10-6 M indomethacin. PAs. Contrary to our observations, Stahl and Lefer (1987) failed to demonstrate vasoactivity in feline renal, superior mesenteric, and coronary arteries in vitro even at high PAF concentrations, suggesting regional differences in the response to this autacoid.
If infused in vivo, PAF was a potent constrictor of coronary arteries (Braquet et aI., 1987) , but the con traction was often preceded by a dilatation (Gold stein et aI., 1986; Braquet et aI., 1987) . This relaxant effect may even be more pronounced than the sub sequent contraction (Mehta et aI., 1986) . Thus, there are several reports of dual (i.e., both relaxant and contractile) effects of PAF in vivo. Such a dual ef fect, presently demonstrated in feline and human brain arteries, may in fact be well adapted for the cerebral circulation. Since PAF is released during inflammation (Goldstein et aI., 1986; Braquet et aI., 1987) , a severe vasospasm might otherwise occur in, for instance, meningitis.
Recently Armstead et aI. (1988) demonstrated that P AF is a potent constrictor of piglet pial arte rioles in vivo. Why, then, was PAF less potent on isolated feline and human cerebral arteries in the present work? Also, why have the effects of PAF on feline coronary arteries differed between no ef fect in vitro (Stahl and Lefer, 1987) and potent ef fects in vivo (Goldstein et aI., 1986; Braquet et aI., 1987) ? In the latter arteries, the difference can eas ily be explained. Several investigators have demon strated that the vasoconstrictor effects of P AF can be eliminated by cyclooxygenase inhibition attained through indomethacin pretreatment (Goldstein et aI., 1986; Braquet et aI., 1987) . Furthermore, PAF markedly increased the production of TxB2 (Gold   stein et aI., 1986; Braquet et aI., 1987) , the stable metabolite of the potent vasoconstrictor TxA2.
Hence, some in vivo effects of PAF seem to be mediated by vasoconstrictor prostanoids (Goldstein et aI., 1986; Braquet et aI., 1987) . Since isolated arteries produce mainly the vasodilator PGI2 (Mon   cada et aI., 1977) , the difference between in vitro and in vivo studies could also be explained in cere bral arteries, had it not been for the finding that P AF failed to increase CSF levels of PGs and TxB2 in newborn pig (Armstead et aI., 1988 ther P AF mediates part of its effects in vivo by release of nonprostanoid substances, or the differ ence in contractile potency between the present study and that of Armstead et aI. (1988) may be attributed to species or age differences (adult cats and humans versus newborn piglets). Another ex planation has been put forward by Kochanek et aI. (1988) . These authors studied cerebrovascular and metabolic effects of P AF in rats and suggested that at least part of the observed decrease in CBF may be due to a PAF-induced impairment of the cere brovascular autoregulation.
In the present study, indomethacin, which blocks cyclooxygenase and thereby eliminates the vascular PG production (Vane, 1971) , had no effect on the contraction induced by 10-6 M PAF in BAs. Like wise, this contraction was unaffected by the Tx re ceptor antagonist AH23848 applied at a concentra tion sufficient to block contractions by both the TxA2-mimetic U46619 and PGF2a in this artery (U ski, 1988) . Similarly, the relaxant effects of PAF in BAs (10-7 -10-6 M PAF) and PAs (10-6 M PAF)
were unaffected by pretreatment with indometha cin. This suggests that the contractile and relaxant effects elicited by these concentrations of PAF are not mediated by TxA2 or PGs.
In conclusion, depending on the experimental conditions, PAF may contract or relax isolated fe line and human cerebral arteries. These effects ap pear to be independent of vascular prostanoid pro duction.
